Inhibiting LSD1 unlocks retinoid AP-1 programming to activate epithelial immunity and skin tumor suppression
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci189044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Nina Kuprasertkul und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and. Hauptthemen laut MEDLINE: Histone Demethylases, Skin Neoplasms, Transcription Factor AP-1, Retinoids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIAMS/NIH, Damon Runyon Cancer Research Foundation.
Abstract (Originalsprache)
Lysine-specific demethylase 1 (LSD1; KDM1A) orchestrates context-dependent chromatin programs, yet its role in epithelial immunity remains largely unknown. Here, we identify LSD1 as a central brake on retinoid-driven and activator protein-1–driven (AP-1–driven) enhancer activation in epidermis and demonstrate that its inhibition induces antitumor immunity. Whereas epidermal LSD1 is required during development, acute loss or topical inhibition in adult skin was tolerated and triggered coordinated expression of retinoic acid signaling, lipid remodeling, and chemokine induction pathways. CUT&RUN profiling revealed that LSD1 occupies enhancer regions enriched for AP-1 motifs at retinoid metabolism, lipid homeostasis, and immune genes. LSD1 loss increased H3K4me1/2 and gene activation at these sites, licensing a poised AP-1–retinoid program. Single-cell spatial analyses showed that discrete keratinocyte subsets initiate retinoid signaling to recruit dendritic cells and activate CD4 + T cell responses. Topical LSD1 inhibition suppressed cutaneous squamous cell carcinoma in 2 models while amplifying keratinocyte–immune cell crosstalk. Functional perturbations revealed that retinoid signaling partially contributes to, whereas CD4 + T cells are essential for, tumor control. These findings define LSD1 as a master repressor of epithelial immune competence and nominate LSD1 inhibition as a therapeutic strategy to activate retinoid–AP-1 enhancer circuits and drive CD4-dependent tumor immunity in skin cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and.
- Penn Epigenetics Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Pediatrics.
- Penn Institute for Biomedical Informatics.
- Department of Cancer Biology.
Förderung
- NIAMS NIH HHS
- NIAMS/NIH
- Damon Runyon Cancer Research Foundation
- Dermatology Foundation
- NIH
Zitieren
APA
Kuprasertkul, N., Moore, A. F., D'souza, C. A., Chini, J., Ko, E. K., Huang, S., Zhang, S., Anderson, A. S., Egolf, S., Pinheiro, L. V., Jaccard, A., Magahis, C. T., Bao, L., Aubert, Y., Olingou, C., Prouty, S. M., Brennan-Crispi, D., Hill, D. A., Seykora, J. T., …, & Capell, B. C. (2026). Inhibiting LSD1 unlocks retinoid AP-1 programming to activate epithelial immunity and skin tumor suppression. Journal of Clinical Investigation. https://doi.org/10.1172/jci189044
Vancouver
Kuprasertkul N, Moore AF, D'souza CA, Chini J, Ko EK, Huang S, et al. Inhibiting LSD1 unlocks retinoid AP-1 programming to activate epithelial immunity and skin tumor suppression. Journal of Clinical Investigation. 2026. doi:10.1172/jci189044
BibTeX
@article{Kuprasertkul2026,
author = {Kuprasertkul, Nina and Moore, Alyssa F and D'souza, Carina A and Chini, Julia and Ko, Eun-Kyung and Huang, Sijia and Zhang, Shuo and Anderson, Ashley S and Egolf, Shaun and Pinheiro, Laura V and Jaccard, Alison and Magahis, Claudia T and Bao, Lydia and Aubert, Yann and Olingou, Cyria and Prouty, Stephen M and Brennan-Crispi, Donna and Hill, David A and Seykora, John T and Wellen, Kathryn E and Capell, Brian C},
title = {Inhibiting LSD1 unlocks retinoid AP-1 programming to activate epithelial immunity and skin tumor suppression},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci189044}
}
EUVIMED